Key Takeaways:
JD Health International Inc. (06618.HK) posted a 6 percent rise in first-quarter non-IFRS net profit to RMB1.874 billion ($260 million), though the modest growth was met with significant bearish sentiment from investors.
Market reaction was overwhelmingly negative, with short-selling volume accounting for an exceptionally high 84.8 percent of the stock's total turnover on the day of the announcement, data from the Hong Kong Exchange shows.
The healthcare arm of e-commerce giant JD.com reported that revenue for the quarter rose 17 percent year-over-year to approximately RMB19.468 billion. Operating income showed a more dramatic spike, surging 70.4 percent to RMB1.825 billion, highlighting a stark divergence from the single-digit growth in net profit.
The results underscore the intense pressure on JD Health to balance top-line growth with sustainable profitability. The disconnect between a 70 percent jump in operating income and a 6 percent gain in adjusted net profit, combined with the massive short interest, suggests deep investor skepticism about the company's cost structure and long-term earnings power.
The extreme short-selling ratio indicates that a large portion of market participants are betting on a decline in JD Health's share price. This level of bearishness is unusual for a company reporting double-digit revenue growth and suggests concerns may lie in margin compression, competitive pressures, or the sustainability of its business model in a tightening regulatory environment.
The health-tech sector globally is facing similar challenges. U.S. telehealth firm Hims & Hers Health, for instance, recently posted a surprise loss and saw margins pressured as it shifted its product mix, according to company filings. This sector-wide trend suggests that high customer acquisition costs and pricing pressures are not unique to JD Health, though the market's reaction to its earnings is particularly severe.
The guidance raise signals management expects AI demand to accelerate. The significant increase in operating income points to underlying strength in core operations, but the high costs associated with sales, marketing, or technology investments may be eroding the bottom line. Investors will be closely watching the company's next earnings release for any improvement in net margins and a potential unwind of the high short interest.
This article is for informational purposes only and does not constitute investment advice.
